• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Sunovion Pharmaceuticals

FDA rejects Sunovion’s NDA for Parkinson’s disease-treating apomorphine sublingual film

January 31, 2019 By Fink Densford

Sunovion Pharmaceuticals said yesterday that the FDA rejected its New Drug Application for its apomorphine sublingual film designed to treat motor fluctuations in people living with Parkinson’s disease. The Marlborough, Mass.-based company’s product is a fast-acting therapy based on a novel formulation of an FDA-approved drug, apomorphine. Sunovion is assessing its apomorphine sublingual film as a therapy […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceutical Tagged With: Sunovion Pharmaceuticals

FDA to review Sunovion’s apomorphine sublingual film for Parkinson’s disease

June 13, 2018 By Sarah Faulkner

Sunovion Pharmaceuticals said today that the FDA accepted its new drug application for a sublingual film designed to treat motor fluctuations in people living with Parkinson’s disease. The U.S. regulatory agency is slated to make a decision regarding Sunovion’s application by January 29. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical Tagged With: Sunovion Pharmaceuticals

Sunovion launches inhaled COPD therapy in U.S.

April 3, 2018 By Sarah Faulkner

Sunovion Pharmaceuticals launched its Lonhala Magnair drug in the U.S. for the long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported today. Sunovion touts its drug as the first nebulized long-acting muscarinic antagonist approved to treat COPD in the U.S. The product is delivered using the Magnair nebulizer […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals, Sunovion Pharmaceuticals

Sunovion seeks FDA nod for sublingual film to treat Parkinson’s disease

March 30, 2018 By Sarah Faulkner

Sunovion Pharmaceuticals submitted a new drug application to the FDA this week for its apomorphine sublingual film designed to treat motor fluctuations experienced by people with Parkinson’s disease. The Marlborough, Mass.-based company is testing the film as a therapy for Parkinson’s patients experiencing “off” episodes – when symptoms that are otherwise controlled by medications resurface. As […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics, Sunovion Pharmaceuticals

Sunovion touts pivotal Ph3 trial for Parkinson’s drug

January 30, 2018 By Sarah Faulkner

Gearing up for a springtime FDA submission, Sunovion Pharmaceuticals reported today that its apomorphine sublingual film succeeded in a pivotal Phase III trial in patients with Parkinson’s disease who experience motor fluctuations. Without revealing the study’s full results, the Marlborough, Mass.-based company said that the trial met its primary and key secondary endpoints and that the drug […]

Filed Under: Clinical Trials, Drug-Device Combinations, Neurological, Pharmaceutical, Wall Street Beat Tagged With: Acorda Therapeutics, Sunovion Pharmaceuticals

Sunovion wins FDA nod for inhaled COPD therapy

December 6, 2017 By Sarah Faulkner

The FDA has approved Sunovion Pharmaceutical‘s Lonhala Magnair system for the long-term treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported today. The drug-device combo, also known as Sun-101/eFlow, is the first nebulized long-acting muscarinic antagonist approved for the treatment of COPD in the U.S. The system includes a portable nebulizer […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals, Sunovion Pharmaceuticals

Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial

July 20, 2017 By Sarah Faulkner

Mylan (NSDQ:MYL) and Theravance Biopharma, Inc. (NSDQ:TBPH) touted safety data yesterday from the late-stage trial of its once-daily inhaled bronchodilator, revefenacin, in patients with chronic obstructive pulmonary disease. If approved, revefenacin would be the first nebulized long-acting muscarinic antagonist on the market for COPD patients in the U.S. Get the full story at our sister site, Drug Delivery Business […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: Boehringer Ingelheim Pharmaceuticals, Mylan, Sunovion Pharmaceuticals, Theravance

Sunovion divests asthma, allergy tech to Covis Pharma

July 13, 2017 By Sarah Faulkner

Sunovion Pharmaceuticals said today that it plans to divest the U.S. market rights for its allergy and asthma products to Covis Pharma, in an effort to narrow its focus to the company’s COPD portfolio. Included in the deal is Sunovion’s Alvesco inhalation aerosol, its Omnaris nasal spray and its Zetonna nasal aerosol. All three products are ciclesonides […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: covispharma, Sunovion Pharmaceuticals

Sunovion seeks FDA nod for COPD treatment – again

June 30, 2017 By Sarah Faulkner

Sunovion Pharmaceuticals said today that the FDA accepted the revised new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The submission follows a complete response letter that the FDA issued Sunovion in May. The Marlborough, Mass.-based company didn’t provide details as to why the FDA denied its initial application. Get the full story at our sister […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Sunovion Pharmaceuticals

FDA deals setback to Sunovion for inhaled COPD therapy

May 30, 2017 By Sarah Faulkner

The FDA issued a complete response letter to Sunovion Pharmaceuticals in regards to the new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo. The investigational eFlow closed-system nebulizer delivers a long-acting muscarinic antagonist bronchodilator, glycopyrrolate, to reduce airflow obstruction in COPD patients. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Respiratory Tagged With: Sunovion Pharmaceuticals

Sunovion, Novartis ink licensing deal for inhaled COPD drugs

December 22, 2016 By Sarah Faulkner

Novartis (NYSE:NVS) said today that it out-licensed its U.S. commercial rights for 3 inhaled chronic obstructive pulmonary disease drugs to Sunovion Pharmaceuticals. Novartis will commercialize the Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler inhalation powders outside of the U.S. The Switzerland-based company will manufacture the powders for Sunovion, according to the agreement. Get the full story […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Respiratory, Wall Street Beat Tagged With: Alphabet (Google), Novartis, Sunovion Pharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS